105807-83-8Relevant articles and documents
Y08060: A Selective BET Inhibitor for Treatment of Prostate Cancer
Xiang, Qiuping,Zhang, Yan,Li, Jiaguo,Xue, Xiaoqian,Wang, Chao,Song, Ming,Zhang, Cheng,Wang, Rui,Li, Chenchang,Wu, Chun,Zhou, Yulai,Yang, Xiaohong,Li, Guohui,Ding, Ke,Xu, Yong
, p. 262 - 267 (2018/03/21)
Prostate cancer is a commonly diagnosed cancer and a leading cause of cancer-related deaths. The bromodomain and extra terminal domain (BET) family proteins have emerged as potential therapeutic targets for the treatment of castration-resistant prostate cancer. A series of 2,2-dimethyl-2H-benzo[b][1,4]oxazin-3(4H)-one derivatives were designed and synthesized as selective bromodomain containing protein 4 (BRD4) inhibitors. The compounds potently inhibit BRD4(1) with nanomolar IC50 values and exhibit high selectivity over most non-BET subfamily members. One of the representative compounds 36 (Y08060) effectively suppresses cell growth, colony formation, and expression of androgen receptor (AR), AR regulated genes, and MYC in prostate cancer cell lines. In in vivo studies, 36 demonstrates a good PK profile with high oral bioavailability (61.54%) and is a promising lead compound for further prostate cancer drug development.
Benzomorpholone derivative as well as preparation method and application of benzomorpholone derivative
-
, (2018/01/11)
The invention belongs to the field of chemical medicines and particularly relates to a benzomorpholone derivative as well as a preparation method and application of the benzomorpholone derivative. The invention provides a benzomorpholone derivative with a structure as shown in the formula I and also provides a preparation method and application of the benzomorpholone derivative. The benzomorpholone derivative provided by the invention is novel in structure, has a good effect on selectively inhibiting BET targets, produces cytotoxicity for various tumor cells to different extents and is a novel BET small-molecule inhibitor. The compound disclosed by the invention has the potential to develop antitumor drugs.
BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS
-
Page/Page column 74-75, (2008/06/13)
The present invention relates to a compound, useful as a mineralocorticoid receptor-modulating agent, of the following formula [I]: wherein Ring A is a benzene ring optionally having a substituent(s) other than R1 etc, R1 is a group